A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

Axel F Grothey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.

Original languageEnglish (US)
Pages (from-to)10-11
Number of pages2
JournalNature Reviews Clinical Oncology
Volume6
Issue number1
StatePublished - Jan 2009

Fingerprint

oxaliplatin
Colorectal Neoplasms
Fluorouracil
Therapeutics
Appointments and Schedules
XELOX
Capecitabine

Keywords

  • 5-fluorouracil
  • Capecitabine
  • Colorectal cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology

Cite this

A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. / Grothey, Axel F.

In: Nature Reviews Clinical Oncology, Vol. 6, No. 1, 01.2009, p. 10-11.

Research output: Contribution to journalArticle

@article{2d1ddd0d5d5f480fa5fdcdba79b5f4c9,
title = "A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer",
abstract = "Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.",
keywords = "5-fluorouracil, Capecitabine, Colorectal cancer, Oxaliplatin",
author = "Grothey, {Axel F}",
year = "2009",
month = "1",
language = "English (US)",
volume = "6",
pages = "10--11",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

AU - Grothey, Axel F

PY - 2009/1

Y1 - 2009/1

N2 - Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.

AB - Oral capecitabine has been shown to be a convenient and well tolerated alternative to intravenous 5-fluorouracil (5-FU) in the treatment of colorectal cancer. The question of whether capecitabine is an adequate and equally effective substitute for infusional 5-FU in combination with oxaliplatin for the treatment of advanced colorectal cancer has long been unanswered. On the basis of results from the randomized, phase III trial by Cassidy et al., capecitabine in combination with oxaliplatin has emerged as a valid treatment alternative to infusional 5-FU in combination with oxaliplatin in patients with advanced colorectal cancer. For patients treated in the US, however, questions about the most appropriate dosage and schedule of capecitabine have not yet been completely resolved. Oncologists will probably have to use a lower starting dose of capecitabine in combination therapies that include oxaliplatin, than that used in this study.

KW - 5-fluorouracil

KW - Capecitabine

KW - Colorectal cancer

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=73949104483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949104483&partnerID=8YFLogxK

M3 - Article

C2 - 18957948

AN - SCOPUS:73949104483

VL - 6

SP - 10

EP - 11

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -